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In this issue of Cancer Cell, Gajjar et al. provide insight into how Mdm2 can both inhibit and enhance p53
activity. In the basal setting, Mdm2 binds p53 and promotes p53 degradation. Under stress conditions,
ATM-dependent phosphorylation of Mdm2 results in its recruitment to p53 mRNA, thereby stimulating p53
translation.The p53 tumor suppressor is a transcrip-
tion factor that is induced in response to
a variety of stress signals (Kruse and Gu,
2009). Under normal conditions, the p53
protein is kept at low levels in cells by
ubiquitination-dependent proteosomal
degradation mediated by its negative
regulator, the E3 ubiquitin ligase Mdm2
(Figure 1A). Mdm2 is also a p53 transcrip-
tional target and thus participates in
a negative feedback loop with p53.
Stress-mediated upregulation of Mdm2
has been considered a means by which
p53 is able to regulate the duration and
amplitude of its cellular effects.
In response to activation of specific
oncogenic pathways, the ARF tumor
suppressor is upregulated. ARF, in turn,
interferes with Mdm2-dependent inhibi-
tion of p53 (Manfredi, 2010) (Figure 1B).
In contrast, stimulation of the p53
pathway by genotoxic stress involves
the DNA damage-activated kinase ATM,
which has been shown to directly phos-
phorylate both p53 and Mdm2 (Kruse
andGu, 2009;Manfredi, 2010) (Figure 1C).
The significance of ATM-dependent
phosphorylation of Mdm2 was confirmed
by the observation that phosphorylation
of serine 395 on Mdm2 led to impaired
p53 degradation (Maya et al., 2001).
Biochemical studies have indicated that
this is likely due to altered oligomerization,thereby attenuating the processivity of the
E3 ligase activity of Mdm2 (Cheng et al.,
2009). DNA damage has also been shown
to induce the relocalization of Mdm2 to
the nucleolus (Bernardi et al., 2004). It
has been proposed that a nucleotide-
binding motif within the Mdm2 E3 ligase
RING domain facilitates nucleolar locali-
zation of Mdm2 (Poyurovsky et al.,
2003). Candeias et al. (2008) then made
the surprising observation that the p53
mRNA itself was able to interact directly
with the RING domain of Mdm2. This
interaction impaired the E3 ligase activity
of Mdm2 and promoted p53 mRNA trans-
lation. It was unclear, however, under
what biological settings such an interac-
tion would have relevance.
In this issue of Cancer Cell, Gajjar et al.
(2012) provide important insight by
demonstrating that the DNA damage-
and ATM-dependent phosphorylation of
Mdm2 on serine 395 promotes the inter-
action of Mdm2 with p53 mRNA. This, in
turn, is needed for p53 stabilization and
apoptotic activity (Gajjar et al., 2012)
(Figure 1D). BymeansofRNAi andoverex-
pression experiments, these authors
show that both ATM and Mdm2 are
required to achieve full p53 apoptotic
activity after DNA damage. Use of an
Mdm2 isoform that does not bind to the
p53 protein shows that a protein-proteininteraction between Mdm2 and p53 is
remarkably dispensable for this. It was
further demonstrated that the interaction
between p53 mRNA and the Mdm2 RING
domain is necessary for p53-dependent
apoptosis after genotoxic stress. Studies
using a mutated p53mRNA that no longer
binds Mdm2 confirmed findings with
amutantMdm2protein that has a reduced
affinity for the mRNA. These intriguing
results support the notion that ATM-medi-
ated phosphorylation of Mdm2 at serine
395 promotes allosteric changes in the
RING domain, which in turn facilitate p53
mRNA binding. Finally, Gajjar et al. (2012)
show that after DNA damage, the interac-
tion between Mdm2 and p53 mRNA
impairs Mdm2-dependent ubiquitination
of p53. Thus, it is argued that the p53
mRNA-MDM2 interaction not only
increases p53 translation but also inhibits
p53 protein degradation as well.
In sum, this study demonstrates that
Mdm2 can act as a positive regulator of
p53 activity after genotoxic stress. It
further provides an additional novel expla-
nation for why Mdm2 is transcriptionally
upregulated by p53 after DNA damage.
The finding that p53 mRNA relocalizes
with Mdm2 in the nucleolus after DNA
damage is especially interesting since
the nucleolus is generally thought of as
the site of ribosomal RNA transcription.21, January 17, 2012 ª2012 Elsevier Inc. 3
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Figure 1. Mdm2 Acts as a Positive or Negative Regulator of p53 Activity in Response to Different Stresses
(A) Under basal conditions, Mdm2 inhibits p53 function by ubiquitination of p53 through its E3 ubiquitin ligase activity, leading to proteosomal-dependent degra-
dation of p53, and by direct interference with the ability of p53 to act as a transcription factor.
(B) Oncogenic signaling has been shown to upregulate ARF at the transcriptional level. ARF binds to Mdm2 and inhibits its E3 ubiquitin ligase activity, thereby
increasing p53 protein levels by alleviating proteosomal-dependent degradation of p53. In this case, Mdm2 behaves as an oncogene. In certain cancers, Mdm2 is
indeed overexpressed.
(C) Other signals such as replicative stress or DNA damage activate the ATM or ATR kinases. ATM, in particular, has been shown to phosphorylate both p53 and
Mdm2 and stabilize p53. The phosphorylation of p53 on serine 15 and serine 37 inhibits its interaction withMdm2, and the phosphorylation ofMdm2 on serine 395
impairs Mdm2-mediated p53 degradation.
(D)Gajjar et al. (2012) demonstrate that phosphorylation ofMdm2on serine 395 induces the binding of p53mRNA to theRINGdomain ofMdm2, the sumoylation of
Mdm2, and the relocalization ofMdm2 to the nucleolus. This p53mRNA-Mdm2 interaction enhances p53 translation and inhibits Mdm2E3 ubiquitin ligase activity
toward p53 protein (Gajjar et al., 2012). Overall, phosphorylatedMdm2 on serine 395 is a positive regulator of p53. In this case, Mdm2 acts as a tumor suppressor.
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PreviewsHowever, several studies support the idea
that it might also be involved in the pro-
cessing or nuclear export of specific
messenger RNAs (Pederson, 2011).
Nevertheless, little is known about the
relationship between mRNA and the
nucleolus. The present study rekindles
the idea that the nucleolus and mRNA
processing are functionally connected.
While these nucleolar events are
intriguing, the key outcome is an enhance-4 Cancer Cell 21, January 17, 2012 ª2012 Elment of p53 protein synthesis, a process
that occurs in the cytoplasm. With this in
mind, a molecular explanation is still
needed for how p53 mRNA is then relo-
cated from the nucleolus to the cytoplasm.
In their previous study, Candeias et al.
(2008) showed that Mdm2 is associated
with polysomes in the cytoplasm, raising
the intriguingpossibility thatMdm2 is actu-
ally exported to the cytoplasm along with
p53 mRNA and that Mdm2 may enhancesevier Inc.p53 translationonce there.Mdm2 isknown
to interact with several ribosomal proteins
(Zhang and Lu, 2009). These interactions
may indeed be at play in this process.
The molecular mechanism by which the
transient Mdm2-dependent nucleolar tar-
geting of p53 mRNA enhances its transla-
tion also remains to be explored.
In summary, the significance of the
study lies not only in its elucidation of
a new role for p53-mediated induction of
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PreviewsMdm2 after DNA damage, it begins to
provide a molecular explanation for how
Mdm2 may act either as an oncogene or
a tumor suppressor, depending upon the
particular context (Manfredi, 2010). This
latter notion has important implications
for the prognosis and treatment of tumors
with aberrant Mdm2 expression.
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The mechanisms leading to the constitutive activation of NF-kB in cancers and the pathways upstream and
downstream of this activation are not fully understood. In this issue of Cancer Cell, Yamagishi et al. demon-
strate that Polycomb-mediated silencing of miR-31 is implicated in the aberrant activation of NF-kB signaling
in tumors.Differential gene expression distinguishes
one cell type from another and enables
cells to build specialized tissues. Once
a cell fate decision is made, the cell must
be able to silence the transcriptional
programs that could potentially lead to
other lineages, because the DNA content
of all cells is the same. Epigenetic factors
play a crucial role in this type of gene
expression regulation. The Polycomb
group of proteins plays a pivotal role in
silencing and in the long-term repression
of genes implicated in cell fate decisions
(Richly et al., 2010). Polycomb proteins
belong either to Polycomb repressive
complex 1 (PRC1) or PRC2. The PRC2
component EZH2 methylates lysine 27 of
histone H3, which attracts the PRC1
complex; the presence of both PRC1 and
PRC2 at promoter regions leads to tran-
scriptional silencing (Richly et al., 2011).
It is now clear that, in addition to epige-
netic complexes, microRNAs (miRNAs)also contribute greatly to posttranscrip-
tional gene regulation.miRNAsareendog-
enous, short (23 nt) RNAs that suppress
gene expression via sequence-specific
interactions with the 30 untranslated
regions of related mRNA targets. miRNAs
affect gene silencing via both translational
inhibition andmRNA degradation. Several
miRNAs have been reported to have
a direct role in oncogenesis, and indeed,
abnormalmiRNA expression is a common
feature of diverse types of cancers, sug-
gesting potential diagnostic or prognostic
biomarker uses.
The NF-kB transcription factor family
regulates the expression of diverse genes
involved in development, cell growth,
immune responses, apoptosis, and
neoplastic transformation. Activation of
NF-kB is a tightly regulated event. In
non-malignant cells, NF-kB is activated
only after appropriate stimulation, after
which it transiently upregulates thetranscription of its target genes. In tumor
cells, different types of molecular alter-
ationsmay result in an impaired regulation
of NF-kB activation and deregulated
expression of target genes due to consti-
tutively active NF-kB. Recent studies
have also demonstrated that miRNAs
modulate NF-kB signaling in both normal
and pathological scenarios (Lu et al.,
2011; Ma et al., 2011).
Adult T cell leukemia/lymphoma (ATL) is
an aggressive neoplasm of mature CD4+
T lymphocytes caused by the human
T cell leukemia/lymphoma virus type 1
(HTLV-1) infection. Aberrant activation of
NF-kB stimulates cell growth and anti-
apoptotic responses in ATL cells and
thus directly participates in ATL patho-
genesis. Recently, correlations between
the epigenetic machinery, NF-kB activa-
tion, and ATL pathology have been sug-
gested (Sasaki et al., 2011). However,
mechanistic insights are lacking. Tax, an21, January 17, 2012 ª2012 Elsevier Inc. 5
